- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01604850
Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION) (FUSION)
A Phase 3, Multicenter, Randomized, Double-Blind, Study to Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
연구 개요
연구 유형
등록 (실제)
단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Auckland, 뉴질랜드, 1640
- Auckland Clinical Studies Limited
-
Christchurch, 뉴질랜드, 8011
- Christchurch Hospital
-
-
-
-
California
-
Coronado, California, 미국, 92118
- Scti Research Foundation
-
Los Angeles, California, 미국, 90027
- Kaiser Permanente
-
Los Angeles, California, 미국, 90036
- Peter J. Ruane, MD, Inc.
-
Los Angeles, California, 미국, 90069
- Anthony Mills MD, Inc.
-
San Diego, California, 미국, 92123
- Medical Associates Research Group, Inc.
-
San Diego, California, 미국, 92103
- UCSD Antiviral Research Center
-
San Diego, California, 미국, 92154
- Kaiser Permanente
-
San Francisco, California, 미국, 94115
- Quest Clinical Research
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- University of Colorado
-
Englewood, Colorado, 미국, 80113
- South Denver Gastroenterology, PC
-
-
District of Columbia
-
Washington, District of Columbia, 미국, 20009
- Whitman Walker Clinic
-
-
Florida
-
Gainesville, Florida, 미국, 32610-0277
- University of Florida
-
Jacksonville, Florida, 미국, 32256
- Borland-Groover Clinic Baptist
-
Miami, Florida, 미국, 33136
- University of Miami
-
New Port Richey, Florida, 미국, 34653
- Advanced Research Institute
-
Orlando, Florida, 미국, 32806
- Internal Medicine Specialists
-
Orlando, Florida, 미국, 32803-1851
- Orlando Immunology Center (ACH)
-
Wellington, Florida, 미국, 33414
- South Florida Center of Gastroenterology, P.A.
-
-
Georgia
-
Atlanta, Georgia, 미국, 30309
- Digestive Healthcare of Georgia
-
Marietta, Georgia, 미국, 30060
- Gastrointestinal Specialists of Georgia, PC
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46237
- Indianapolis Gastroenterology Research Foundation
-
-
Kentucky
-
Bowling Green, Kentucky, 미국, 42101
- Graves-Gilbert Clinic
-
-
Louisiana
-
Baton Rouge, Louisiana, 미국, 70809
- Gastroenterology Associates, LLC
-
-
Maryland
-
Lutherville, Maryland, 미국, 21093
- Johns Hopkins University
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02114-2696
- Massachusetts General Hospital
-
Boston, Massachusetts, 미국, 02115
- Beth Israel Deaconess Medical Center
-
Springfield, Massachusetts, 미국, 01105
- The Research Institute
-
-
Michigan
-
Novi, Michigan, 미국, 48377
- Henry Ford Health System
-
-
Minnesota
-
Minneapolis, Minnesota, 미국, 55414
- Minnesota Gastroenterology, P.A.
-
-
Missouri
-
Kansas City, Missouri, 미국, 64131
- Kansas City Gastroenterology and Hepatology
-
-
New Jersey
-
Berlin, New Jersey, 미국, 08009
- Comprehensive Clinical Research
-
Hillsborough, New Jersey, 미국, 08844
- ID Care
-
-
New Mexico
-
Santa Fe, New Mexico, 미국, 87505
- Southwest C.A.R.E. Center
-
-
New York
-
Binghamton, New York, 미국, 13903
- Binghamton Gastroenterology Associates
-
New York, New York, 미국, 10029
- Mount Sinai School of Medicine
-
-
North Carolina
-
Asheville, North Carolina, 미국, 28801
- Asheville Gastroenterology Associates, P.A.
-
Durham, North Carolina, 미국, 27710
- Duke University Medical Center
-
Winston-Salem, North Carolina, 미국, 27103
- Digestive Health Specialists, PA
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19104
- University of Pennsylvania
-
-
Rhode Island
-
Providence, Rhode Island, 미국, 02906
- The Miriam Hospital
-
Providence, Rhode Island, 미국, 02905
- University Gastroenterology
-
-
Tennessee
-
Germantown, Tennessee, 미국, 38138
- Gastro One
-
Nashville, Tennessee, 미국, 37211
- Nashville Gastrointestinal Specialists, Inc
-
-
Texas
-
Arlington, Texas, 미국, 76012
- Texas Clinical Research Institute, LLC
-
Dallas, Texas, 미국, 75219
- Southwest Infectious Disease Clinical Research, Inc.
-
San Antonio, Texas, 미국, 78215
- Alamo Medical Research
-
-
Virginia
-
Fairfax, Virginia, 미국, 22031
- Metropolitan Research
-
Falls Church, Virginia, 미국, 22042
- Inova Fairfax Hospital Center for Liver Diseases
-
Norfolk, Virginia, 미국, 23502
- Digestive and Liver Disease Specialists
-
Richmond, Virginia, 미국, 23226
- Bon Secours St. Mary's Hospital of Richmond, Inc.
-
-
Washington
-
Seattle, Washington, 미국, 98101
- Virginia Mason Medical Center
-
-
-
-
Alberta
-
Calgary, Alberta, 캐나다, T2N 4Z6
- University of Calgary
-
Edmonton, Alberta, 캐나다, T6G 2X8
- University of Alberta Hospital
-
Edmonton, Alberta, 캐나다, T6G 2B7
- University of Alberta Hospital
-
-
British Columbia
-
Vancouver, British Columbia, 캐나다, V5Z 1M9
- Gordon & Leslie Diamond Health Care Centre
-
Vancouver, British Columbia, 캐나다, V6Z 2C9
- University of British Columbia
-
Vancouver, British Columbia, 캐나다, V6Z 2K5
- (G.I.R.I.) Gastrointestinal Research Institute
-
-
Manitoba
-
Winnipeg, Manitoba, 캐나다, R3E 3P4
- University of Manitoba Health Sciences Center
-
-
Ontario
-
Ottawa, Ontario, 캐나다, K1H 8L6
- The Ottawa Hospital
-
Toronto, Ontario, 캐나다, M5T 2S8
- Toronto Western Hospital
-
Toronto, Ontario, 캐나다, M6H 3M1
- Toronto Liver Centre
-
Toronto, Ontario, 캐나다, M5G 1X5
- Mount Sinai Hospital
-
-
Quebec
-
Montreal, Quebec, 캐나다, H2X 3J4
- Hopital St. Luc
-
-
-
-
-
San Juan, 푸에르토 리코, 00927
- Fundacion de Investigacion de Diego
-
San Juan, 푸에르토 리코, 00909-1711
- Clinical Research Puerto Rico Inc
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Infection with HCV genotype 2 or 3
- Had cirrhosis determination
- Prior treatment failure
- Screening laboratory values within defined thresholds
- Subject had not been treated with any investigational drug or device within 30 days of the screening visit
- Use of highly effective contraception methods if female of childbearing potential or sexually active male
Exclusion Criteria:
- Prior exposure to an direct-acting antiviral targeting the HCV nonstructural protein (NS)5B polymerase
- Pregnant or nursing female or male with pregnant female partner
- Current or prior history of clinical hepatic decompensation
- History of clinically significant illness or any other major medical disorder that may have interfered with subject treatment, assessment or compliance with the protocol
- Excessive alcohol ingestion or significant drug abuse
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: SOF+RBV+placebo
Participants were randomized to receive SOF+RBV for 12 weeks followed by placebo to match SOF plus placebo to match RBV for 4 weeks.
|
Sofosbuvir (SOF) 400 mg tablet was administered orally once daily.
다른 이름들:
Ribavirin (RBV) tablets was administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
Placebo to match SOF was administered orally once daily.
Placebo to match RBV was administered orally twice daily.
|
실험적: SOF+RBV
Participants were randomized to receive SOF+RBV for 16 weeks.
|
Sofosbuvir (SOF) 400 mg tablet was administered orally once daily.
다른 이름들:
Ribavirin (RBV) tablets was administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Percentage of Participants Achieving SVR12
기간: Posttreatment Week 12
|
SVR12 was defined as HCV RNA < the lower limit of quantitation (LLOQ, ie, < 25 IU/mL) 12 weeks after cessation of therapy. For the purposes of this efficacy analysis, the posttreatment period began after the end of active treatment (following Week 12 for the SOF+RBV+placebo arm, and Week 16 for the SOF+RBV arm). |
Posttreatment Week 12
|
Adverse Events Leading to Permanent Discontinuation of Study Drug
기간: Baseline to Week 16
|
Adverse events which led to permanent discontinuation of study drug may or may not have been related to study treatment.
|
Baseline to Week 16
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Percentage of Participants Achieving SVR4
기간: Posttreatment Week 4
|
SVR4 was defined as HCV RNA < LLOQ 4 weeks after cessation of therapy. For the purposes of this efficacy analysis, the posttreatment period began after the end of active treatment (following Week 12 for the SOF+RBV+placebo arm, and Week 16 for the SOF+RBV arm). |
Posttreatment Week 4
|
Percentage of Participants Achieving SVR24
기간: Posttreatment Week 24
|
SVR24 was defined as HCV RNA < LLOQ 24 weeks after cessation of therapy. For the purposes of this efficacy analysis, the posttreatment period began after the end of active treatment (following Week 12 for the SOF+RBV+placebo arm, and Week 16 for the SOF+RBV arm). |
Posttreatment Week 24
|
Percentage of Participants With Viral Breakthrough
기간: Up to 16 weeks
|
Viral breakthrough was defined as HCV RNA ≥ LLOQ after having previously had HCV RNA < LLOQ while receiving treatment, confirmed with 2 consecutive values (second confirmation value could be posttreatment), or last available on-treatment measurement with no subsequent follow-up values. For the purposes of this efficacy analysis, assessments were made during active treatment (up to Week 12 for the SOF+RBV+placebo arm, and Week 16 for the SOF+RBV arm). |
Up to 16 weeks
|
Percentage of Participants With Viral Relapse
기간: End of treatment to posttreatment Week 24
|
Viral relapse was defined as HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA < LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement. For the purposes of this efficacy analysis, the posttreatment period began after the end of active treatment (following Week 12 for the SOF+RBV+placebo arm, and Week 16 for the SOF+RBV arm). |
End of treatment to posttreatment Week 24
|
공동 작업자 및 조사자
스폰서
간행물 및 유용한 링크
일반 간행물
- Younossi ZM, Stepanova M, Sulkowski M, Naggie S, Puoti M, Orkin C, Hunt SL. Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes. J Infect Dis. 2015 Aug 1;212(3):367-77. doi: 10.1093/infdis/jiv005. Epub 2015 Jan 12.
- Stepanova M, Nader F, Cure S, Bourhis F, Hunt S, Younossi ZM. Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens. Aliment Pharmacol Ther. 2014 Sep;40(6):676-85. doi: 10.1111/apt.12880. Epub 2014 Jul 15.
- Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR; POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013 May 16;368(20):1867-77. doi: 10.1056/NEJMoa1214854. Epub 2013 Apr 23.
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- GS-US-334-0108
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
만성 C형 간염에 대한 임상 시험
-
Hospital Clinic of BarcelonaAstraZeneca완전한CTO(Chronic Total Occlusion)를 위한 PCI(Percutaneous Coronary Intervention)를 받을 예정인 환자스페인
-
Meir Medical Center완전한디지털 스테레오 광 디스크 이미지에서 C/D 비율을 측정하는 새로운 기술 개발 | C/D 측정의 관찰자 내 재현성 | C/D 측정의 관찰자 간 가변성
-
University Hospital, GrenobleClinical Investigation Centre for Innovative Technology Network완전한
-
Haisco Pharmaceutical Group Co., Ltd.완전한
-
University Hospital, Caen완전한
-
University of Sao Paulo General HospitalInCor Heart Institute; Chinese Academy of Medical Sciences, Fuwai Hospital; Beneficência... 그리고 다른 협력자들알려지지 않은
SOF에 대한 임상 시험
-
McMaster UniversityAgency for Healthcare Research and Quality (AHRQ); Grading of Recommendations Assessment...완전한
-
Sanjay Gandhi Postgraduate Institute of Medical...Ram Manohar Lohia Institute of Medical Sciences, Lucknow종료됨
-
Humanity and Health Research CentreBeijing 302 Hospital; Nanfang Hospital of Southern Medical University모병
-
Gilead Sciences종료됨C형 간염 바이러스 감염프랑스, 스페인, 미국, 호주, 캐나다, 독일, 영국, 이탈리아, 뉴질랜드, 푸에르토 리코
-
Kirby Institute완전한C 형 간염호주, 미국, 영국, 뉴질랜드, 스위스, 캐나다, 독일, 네덜란드
-
Stanford UniversityGilead Sciences완전한
-
Humanity and Health Research CentreBeijing 302 Hospital완전한
-
Humanity and Health Research CentreUniversity of Maryland; Emory University; Beijing 302 Hospital빼는
-
Beni-Suef University완전한만성 C형 간염 바이러스 감염